<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883528</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00108314</org_study_id>
    <nct_id>NCT04883528</nct_id>
  </id_info>
  <brief_title>Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019</brief_title>
  <acronym>PARACOR-19</acronym>
  <official_title>Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo&#xD;
      on markers of cardiac injury, structure, and function among patients who recovered from acute&#xD;
      COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in high-sensitivity troponin T</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in soluble ST2</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-reactive peptide</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PINP</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Galectin-3</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NT-proBNP</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in GDF-15</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in interleukin-6</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac MRI measures</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in focal fibrosis by delayed-enhancement on cardiac MRI</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in focal fibrosis by percentage of left ventricular myocardial mass on cardiac MRI</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EuroQOL-5 dimensions utility score</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EuroQOL-5 dimensions visual analog scale</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.&#xD;
Sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.&#xD;
Other Name: LCZ696</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Initial dose for patients randomized to sacubitril/valsartan matching placebo will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.&#xD;
Sacubitril/valsartan matching placebo with minimum dose matching the 24/26 mg dose, maximum dose matching the 97/103 mg dose, adminstered twice daily orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril / Valsartan Oral Tablet [Entresto]</intervention_name>
    <description>sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.</description>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <other_name>LCZ696</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with a history of laboratory proven-diagnosis of COVID-19 who is 4-16 weeks&#xD;
             from their last positive COVID-19 test&#xD;
&#xD;
          2. Systolic blood pressure ≥100 mmHg at screening&#xD;
&#xD;
          3. ≥18 years of age&#xD;
&#xD;
          4. Successful collection of baseline serum biomarkers&#xD;
&#xD;
          5. Successful completion of baseline EQ-5D questionnaire&#xD;
&#xD;
          6. Successful completion of baseline CMR study (CMR sub-study only)&#xD;
&#xD;
          7. High-sensitivity troponin T at or above the level of detection on screening labs&#xD;
&#xD;
          8. Presence of ≥1 of the following:&#xD;
&#xD;
               1. Age ≥60&#xD;
&#xD;
               2. History of atherosclerotic cardiovascular disease (ASCVD), including myocardial&#xD;
                  infarction, coronary artery disease, ischemic stroke/transient ischemic attack,&#xD;
                  or peripheral artery disease&#xD;
&#xD;
               3. Diabetes mellitus (Type 1 or Type 2)&#xD;
&#xD;
               4. Body mass index ≥35 kg/m2&#xD;
&#xD;
               5. eGFR 30-60 ml/min/1.73m2&#xD;
&#xD;
               6. History of atrial fibrillation/flutter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fever within the past 96 hours of &gt;100.3 degrees Fahrenheit&#xD;
&#xD;
          2. Actively receiving therapy with an angiotensin-converting enzyme inhibitor (ACEI),&#xD;
             angiotensin II receptor blocker (ARB), aliskiren, or sacubitril/valsartan&#xD;
&#xD;
          3. Last known left ventricular ejection fraction of ≤40%&#xD;
&#xD;
          4. eGFR &lt;30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy&#xD;
&#xD;
          5. Serum potassium &gt;5.0 mEq/L on screening labs&#xD;
&#xD;
          6. Prior intolerance, allergy or angioedema to ACEI, ARB, or sacubitril/valsartan&#xD;
&#xD;
          7. Pregnant or breast-feeding&#xD;
&#xD;
          8. In women of childbearing age, unwillingness to use birth control for the duration of&#xD;
             the study&#xD;
&#xD;
          9. History of heart transplant or durable left ventricular assist device&#xD;
&#xD;
         10. Currently implanted permanent pacemaker, defibrillator, or other device that would&#xD;
             preclude CMR testing (CMR sub-study only)&#xD;
&#xD;
         11. Currently participating in another trial of an investigational medication or device&#xD;
             for COVID-19.&#xD;
&#xD;
         12. Any other condition that in the judgment of the investigator would jeopardize the&#xD;
             patient's compliance with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Greene, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Michael Felker, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Greene, MD</last_name>
    <phone>919 684 8111</phone>
    <email>stephen.greene@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Greene, MD</last_name>
      <phone>919-684-8111</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sacubitril/valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

